Cel­gene, Io­n­is ink Chi­na drug de­vel­op­ment pacts; Mo­tif touts pos­i­tive PhI­II an­tibi­ot­ic da­ta

A host of biotech star­tups in Chi­na have been mak­ing the trek to the US to part­ner on promis­ing ex­per­i­men­tal ther­a­pies. And we have news of two new pacts this week:

→ Shang­hai-based An­ten­gene Cor­po­ra­tion inked a col­lab­o­ra­tive part­ner­ship and de­fin­i­tive li­cens­ing agree­ment with Cel­gene Cor­po­ra­tion for its TORC1/TORC2 in­hibitor CC- 223 cov­er­ing Chi­na and oth­er Asian na­tions. An­ten­gene will be ful­ly re­spon­si­ble for the clin­i­cal de­vel­op­ment and com­mer­cial­iza­tion of CC-223 for the de­fined ter­ri­to­ries.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER